- Zacks•2 days ago
Alexion Pharmaceuticals, Inc. (ALXN) announced that it has submitted an application to Japan's Ministry of Labour and Welfare (MHLW) for the label expansion for Soliris to treat patients with refractory generalized myasthenia gravis (gMG).
- Business Wire•2 days ago
Alexion Submits Application in Japan for Soliris® (Eculizumab) as a Potential Treatment for Patients with Refractory Generalized Myasthenia Gravis (gMG)
Alexion Pharmaceuticals, Inc. announced today that it has submitted an application to Japan’s Ministry of Labour and Welfare to extend the indication for Soliris® as a potential treatment for patients with refractory generalized myasthenia gravis who are anti-acetylcholine receptor antibody-positive.
- Zacks•7 days ago
Alexion Pharmaceuticals, Inc. (ALXN) has recently licensed Arbutus Biopharma proprietary LNP technology for use in rare disease programs.
ALXN : Summary for Alexion Pharmaceuticals, Inc. - Yahoo Finance
Alexion Pharmaceuticals, Inc. (ALXN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||100.76 x 100|
|Ask||151.00 x 100|
|Day's Range||118.73 - 121.37|
|52 Week Range||109.12 - 162.00|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||67.76|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|